Nano-Wrapped Vancomycin Derivative Can Be Taken Orally and Still Fight Systemic Infections in Mice
A liposomal nanocarrier with cell-penetrating peptides enabled oral delivery of the vancomycin derivative FU002, achieving significant therapeutic efficacy against systemic bacterial infection in mice.
Quick Facts
What This Study Found
Liposomal FU002 coated with cyclic cell-penetrating peptides achieved oral bioavailability in rats and significant therapeutic efficacy against systemic infection in mice when administered orally, while maintaining antimicrobial activity in vitro and in vivo.
Key Numbers
Surface-modified liposomes showed significantly improved oral bioavailability compared to unformulated FU002.
How They Did This
FU002 was incorporated into tetraether lipid-stabilized liposomes modified with cyclic cell-penetrating peptides. Caco-2 cell binding and cytotoxicity were assessed in vitro. Pharmacokinetics were studied in rats (oral vs. IV). Antimicrobial activity was tested in vitro and in a murine systemic infection model with oral dosing.
Why This Research Matters
Turning injectable-only antibiotics into oral drugs would be transformative for healthcare — reducing hospitalizations, improving patient comfort, and expanding access in resource-limited settings. This proof-of-concept shows that nanotechnology can enable oral delivery of peptide antibiotics that were previously impossible to take by mouth.
The Bigger Picture
Antibiotic resistance is a growing global crisis, and many of the most potent antibiotics (including vancomycin derivatives) can only be given IV. Making these drugs orally bioavailable through nanocarrier technology could dramatically change how we treat serious infections — potentially enabling outpatient treatment of conditions that currently require hospitalization for IV antibiotics.
What This Study Doesn't Tell Us
Early-stage preclinical study in rodents — oral bioavailability improvement was demonstrated but absolute values weren't detailed in the abstract. The complexity and cost of manufacturing liposomal formulations with cell-penetrating peptides may limit scalability. Long-term safety of the nanocarrier components is unknown. Human gut conditions may differ from rodent models.
Questions This Raises
- ?What is the absolute oral bioavailability of liposomal FU002 compared to IV administration?
- ?Could this nanocarrier platform be adapted for other peptide antibiotics or antimicrobial peptides?
- ?Is the manufacturing process scalable and cost-effective enough for clinical development?
Trust & Context
- Key Stat:
- Oral efficacy in systemic infection Liposomal FU002 delivered orally produced significant therapeutic benefit in a mouse model of systemic bacterial infection — achieving what free vancomycin derivatives cannot
- Evidence Grade:
- Preliminary evidence from a preclinical proof-of-concept study in rodents. The results are promising but far from clinical application — human bioavailability, safety, and efficacy remain untested.
- Study Age:
- Published in 2024, representing cutting-edge nanotechnology approaches to one of pharmaceutical science's biggest challenges — oral delivery of peptide drugs.
- Original Title:
- Oral Delivery of the Vancomycin Derivative FU002 by a Surface-Modified Liposomal Nanocarrier.
- Published In:
- Advanced healthcare materials, 13(14), e2303654 (2024)
- Authors:
- Werner, Julia, Umstätter, Florian, Hertlein, Tobias, Mühlberg, Eric, Beijer, Barbro, Wohlfart, Sabrina, Zimmermann, Stefan, Haberkorn, Uwe, Ohlsen, Knut, Fricker, Gert, Mier, Walter, Uhl, Philipp
- Database ID:
- RPEP-09524
Evidence Hierarchy
Frequently Asked Questions
Why can't vancomycin normally be taken as a pill?
Vancomycin is a large, complex peptide molecule that gets destroyed by stomach acid and digestive enzymes, and even if it survives, it's too big and poorly absorbed to cross the intestinal wall into the bloodstream. When taken orally, it stays in the gut — useful for gut infections like C. diff, but useless for infections elsewhere in the body. That's why serious infections requiring vancomycin need IV administration in a hospital.
What are cell-penetrating peptides and how do they help?
Cell-penetrating peptides (CPPs) are short amino acid sequences that can cross cell membranes — essentially molecular keys that unlock the body's cellular barriers. By attaching CPPs to the surface of the drug-carrying liposomes, researchers gave them the ability to cross the intestinal wall and deliver their antibiotic cargo into the bloodstream. It's like adding a GPS and a pass card to a delivery truck so it can navigate through security checkpoints.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09524APA
Werner, Julia; Umstätter, Florian; Hertlein, Tobias; Mühlberg, Eric; Beijer, Barbro; Wohlfart, Sabrina; Zimmermann, Stefan; Haberkorn, Uwe; Ohlsen, Knut; Fricker, Gert; Mier, Walter; Uhl, Philipp. (2024). Oral Delivery of the Vancomycin Derivative FU002 by a Surface-Modified Liposomal Nanocarrier.. Advanced healthcare materials, 13(14), e2303654. https://doi.org/10.1002/adhm.202303654
MLA
Werner, Julia, et al. "Oral Delivery of the Vancomycin Derivative FU002 by a Surface-Modified Liposomal Nanocarrier.." Advanced healthcare materials, 2024. https://doi.org/10.1002/adhm.202303654
RethinkPeptides
RethinkPeptides Research Database. "Oral Delivery of the Vancomycin Derivative FU002 by a Surfac..." RPEP-09524. Retrieved from https://rethinkpeptides.com/research/werner-2024-oral-delivery-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.